Literature DB >> 26968666

Antiarrhythmic Drug Therapy for Atrial Fibrillation.

Muhammad Rizwan Sardar1, Wajeeha Saeed2, Peter R Kowey3.   

Abstract

Atrial fibrillation (AF) is the most frequently encountered arrhythmia. Prevalence increases with advancing age and so as its associated comorbidities, like heart failure. Choice of pharmacologic therapy depends on whether the goal of treatment is maintaining sinus rhythm or tolerating AF with adequate control of ventricular rates. Antiarrhythmic therapy and conversion of AF into sinus rhythm comes with the side effect profile, and we should select best antiarrhythmic therapy, individualized to the patient. New antiarrhythmic drugs are being tested in clinical trials. Drugs that target remodeling and inflammation are being tested for their use as prevention of AF or as upstream therapy.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antiarrhythmic; Atrial fibrillation; Cardioversion; Pharmacologic therapy; Prevention; Rate control; Rhythm control; Upstream therapy

Mesh:

Substances:

Year:  2016        PMID: 26968666     DOI: 10.1016/j.hfc.2015.08.017

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  5 in total

Review 1.  Mechanisms and Drug Development in Atrial Fibrillation.

Authors:  David Calvo; David Filgueiras-Rama; José Jalife
Journal:  Pharmacol Rev       Date:  2018-07       Impact factor: 25.468

Review 2.  Gene therapy for atrial fibrillation - How close to clinical implementation?

Authors:  Amar Trivedi; Jacob Hoffman; Rishi Arora
Journal:  Int J Cardiol       Date:  2019-08-07       Impact factor: 4.164

3.  Prevention of Atrial Fibrillation by Using Sarcoplasmic Reticulum Calcium ATPase Pump Overexpression in a Rabbit Model of Rapid Atrial Pacing.

Authors:  Hong Li Wang; Xian Hui Zhou; Zhi Qiang Li; Ping Fan; Qi Na Zhou; Yao Dong Li; Yue Mei Hou; Bao Peng Tang
Journal:  Med Sci Monit       Date:  2017-08-16

4.  Atrial fibrosis underlying atrial fibrillation (Review).

Authors:  Chang Yi Li; Jing Rui Zhang; Wan Ning Hu; Song Nan Li
Journal:  Int J Mol Med       Date:  2021-01-15       Impact factor: 4.101

Review 5.  Pulmonary Delivery of Antiarrhythmic Drugs for Rapid Conversion of New-Onset Atrial Fibrillation.

Authors:  Richard L Verrier; Luiz Belardinelli
Journal:  J Cardiovasc Pharmacol       Date:  2020-04       Impact factor: 3.271

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.